Bison Wealth LLC Lowers Stock Position in Stryker Co. (NYSE:SYK)

Bison Wealth LLC lessened its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 88.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 830 shares of the medical technology company's stock after selling 6,508 shares during the period. Bison Wealth LLC's holdings in Stryker were worth $299,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Kohmann Bosshard Financial Services LLC bought a new position in shares of Stryker during the fourth quarter worth about $25,000. Rakuten Securities Inc. raised its holdings in Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Stryker in the 4th quarter valued at $30,000. BankPlus Trust Department acquired a new stake in Stryker during the 4th quarter worth about $33,000. Finally, VSM Wealth Advisory LLC acquired a new stake in Stryker during the fourth quarter worth approximately $36,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Barclays raised their price objective on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. JPMorgan Chase & Co. raised their price target on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Argus set a $450.00 price objective on shares of Stryker in a report on Monday, February 3rd. Royal Bank of Canada boosted their target price on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Finally, The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $426.53.

Insider Activity

In related news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.90% of the company's stock.

Stryker Stock Performance

Shares of NYSE SYK traded up $4.61 during midday trading on Friday, hitting $378.60. The company's stock had a trading volume of 3,709,100 shares, compared to its average volume of 1,355,896. The firm has a market capitalization of $144.51 billion, a price-to-earnings ratio of 48.79, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a fifty day moving average price of $366.38 and a 200 day moving average price of $373.82. Stryker Co. has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.50 earnings per share. On average, research analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend was Monday, March 31st. Stryker's payout ratio is presently 45.41%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.